FLNA — Filana Therapeutics Share News
0.000.00%
Last trade - 00:00Cassava charged by US SEC for misleading Alzheimer's drug trial claims, shares fall
US charges Cassava Sciences, two former executives for misleading claims about Alzheimer’s clinical trial
Brief: Cassava Sciences Announces Completion Of An Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials
Biotech firm Cassava Sciences names Richard Barry as new CEO
Cassava Sciences Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cassava Sciences Q2 Basic EPS USD 0.13
Cassava Sciences Inc expected to post a loss of 40 cents a share - Earnings Preview
Biotech firm drops defamation suit against short-sellers after researcher charged
Cassava Sciences Inc expected to post a loss of 40 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Walt Disney, Mattel, Tellurian
U.S. STOCKS ON THE MOVE-Verizon Communications, Reddit, Starbucks
U.S. STOCKS ON THE MOVE-Cassava Sciences, Crowdstrike Holdings, crypto stocks
Brief: Cassava Sciences's First Phase 3 Trial Expected To Read Out By December 2024
Cassava up; co expects late-stage trial data for Alzheimer's drug in December
Press Digest: New York Times business news - July 19
Cassava Sciences CEO Remi Barbier steps down (updated)
Biotech firm Cassava Sciences' CEO steps down
Brief: Cassava Sciences Announces Changes in Executive Leadership
U.S. STOCKS ON THE MOVE-Tesla, Apple, AMD, Merck